Paolo Tosco

List of Publications by Citations

Source: https://exaly.com/author-pdf/2411166/paolo-tosco-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31 papers	832 citations	17 h-index	28 g-index
33 ext. papers	938 ext. citations	5.3 avg, IF	4.15 L-index

#	Paper	IF	Citations
31	Open3DQSAR: a new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields. *Journal of Molecular Modeling*, **2011**, 17, 201-8	2	109
30	3D-QSAR reloaded: Open3DALIGN meets COSMOsar3D. *Journal of Cheminformatics*, **2013**, 5,	8.6	78
29	Open3DALIGN: an open-source software aimed at unsupervised ligand alignment. *Journal of Computer-Aided Molecular Design*, **2011**, 25, 777-83	4.2	74
28	Bringing the MMFF force field to the RDKit: implementation and validation. *Journal of Cheminformatics*, **2014**, 6,	8.6	70
27	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. *Journal of Medicinal Chemistry*, **2007**, 50, 1449-57	8.3	52
26	Physicochemical Profiling of Sartans: A Detailed Study of Ionization Constants and Distribution Coefficients. *Helvetica Chimica Acta*, **2008**, 91, 468-482	2	43
25	Edaravone derivatives containing NO-donor functions. *Journal of Medicinal Chemistry*, **2009**, 52, 574-8	8.3	31
24	Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. *ChemMedChem*, **2009**, 4, 939-45	3.7	30
23	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 715-9	2.9	28
22	COSMOsar3D: molecular field analysis based on local COSMO profiles. *Journal of Chemical Information and Modeling*, **2012**, 52, 2157-64	6.1	26
21	New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold. *European Journal of Medicinal Chemistry*, **2012**, 49, 102-9	6.8	25
20	1,2,5-Oxadiazole analogues of leflunomide and related compounds. *European Journal of Medicinal Chemistry*, **2011**, 46, 383-92	6.8	23
19	A 3D-QSAR-driven approach to binding mode and affinity prediction. *Journal of Chemical Information and Modeling*, **2012**, 52, 302-7	6.1	22
18	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2428-38	3.4	21
17	[3-(1H-imidazol-4-yl)propyl]guanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 1197-205	3.4	21
16	The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors. *Journal of Molecular Modeling*, **2013**, 19, 1099-107	2	18
15	Multitarget drugs: Focus on the NO-donor hybrid drugs. *Pure and Applied Chemistry*, **2008**, 80, 1693-1701	2.1	17

List of Publications

14	Design and Synthesis of a (1)(3)-Cyclodextrin Oligomer: A New Platform with Potential Application as a Dendrimeric Multicarrier. *Chemistry - A European Journal*, **2013**, 19, 12086-92	4.8	16
13	A mechanistic hypothesis for the aspirin-induced switch in lipid mediator production by cyclooxygenase-2. *Journal of the American Chemical Society*, **2013**, 135, 10404-10	16.4	16
12	6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity. *European Journal of Medicinal Chemistry*, **2013**, 68, 333-8	6.8	14
11	Complementary three-dimensional quantitative structure-activity relationship modeling of binding affinity and functional potency: a study on alpha4beta2 nicotinic ligands. *Journal of Medicinal Chemistry*, **2009**, 52, 2311-6	8.3	13
10	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds. *Journal of Molecular Modeling*, **2008**, 14, 279-91	2	13
9	Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4750-9	3.4	13
8	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *Journal of Pineal Research*, **2007**, 42, 371-85	10.4	12
7	A new class of NO-donor H3-antagonists. *Il Farmaco*, **2004**, 59, 359-71		11
6	SDF2XYZ2SDF: how to exploit TINKER power in cheminformatics projects. *Journal of Molecular Modeling*, **2011**, 17, 3021-3	2	9
5	Thymopentin down-regulates both activity and expression of iNOS in blood cells of S□ary syndrome patients. *Nitric Oxide - Biology and Chemistry*, **2012**, 27, 143-9	5	8
4	Nitrooxyacyl derivatives of salicylic acid: aspirin-like molecules that covalently inactivate cyclooxygenase-1. *ChemMedChem*, **2011**, 6, 523-30	3.7	7
3	Non-imidazole histamine NO-donor H3-antagonists. *Il Farmaco*, **2005**, 60, 507-12		5
2	Structure-antioxidant activity relationships in a series of NO-donor phenols. *ChemMedChem*, **2008**, 3, 1443-8	3.7	4
1	The integration of Open3DTOOLS into the RDKit and KNIME. *Journal of Cheminformatics*, **2014**, 6,	8.6	3